Labcorp Holdings Inc.

Labcorp Holdings Inc. is an American clinical laboratory and drug development services company that operates the largest network of clinical testing laboratories in the United States, generating $13.95 billion in revenue in fiscal 2025. Alongside Quest Diagnostics, Labcorp forms one half of the duopoly that runs the backbone of U.S. outpatient diagnostics — processing roughly 600 million tests annually across a network of patient service centers, hospital partnerships, and regional laboratories. The company also operates a global central laboratory and early-stage contract research business through its Biopharma Laboratory Services segment, which supported the development of more than 85% of new drugs approved by the FDA in 2025.

This is a story about a cash-generative franchise anchored by an unavoidable consumer of healthcare spending — routine blood work — paired with a growth-oriented drug development services business. The Fortrea spin-off in June 2023 marked the end of a decade-long experiment with full-service CRO ownership and returned the company to something closer to its core: high-volume, high-reliability diagnostic testing with a scientific edge in specialty areas like oncology and neurology. Since the spin, GAAP operating margins have expanded from 6.0% in FY2023 to 10.9% in FY2025, net earnings from continuing operations have more than doubled, and the company has deployed over $1.4 billion on acquisitions to consolidate hospital outreach laboratories and expand its geographic reach.

The file turns on a single question: whether Labcorp's competitive position in diagnostics is durable enough to sustain mid-single-digit organic growth as reimbursement policy tightens, or whether the structural advantages of scale — the courier networks, the reference lab density, the payer contracts — are eroding faster than management's specialty-testing and hospital-partnership strategy can offset.